AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing TumorsWeining Weng(Sun Yat-sen University), Xun Meng(Walmart (United States))Molecular Cancer TherapeuticsJune 11, 202310.1158/1535-7163.mct-23-0198Cited by 24SaveCiteExport RISWatch citationsRelated PapersA Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma|Cancer Research|2023|14